While far from genome-wide statistical significance for gene-based testing (p < 2.7 × 10−6), we found nominally significant associations of the predicted damaging CCR2 variants with myocardial infarction (OR: 0.60, 95%CI: 0.40–0.90, p = 0.008) and coronary artery disease (OR: 0.76, 95%CI: 0.59–0.99, p = 0.03), as well as directionally consistent associations with the odds of all other examined outcomes (ischemic stroke, peripheral artery disease, abdominal aortic aneurysm, Fig. 2A). Here, CCR2 is linked to ischemic stroke.